PPARG and breast carcinoma: Unfortunately, TZDs appeared to only exert modest antiproliferative effects against pleomorphic/myxoid round-cell liposarcomas [9], but patients with heavily pretreated advanced carcinomas including breast cancer [12], colorectal cancer [13], and prostate cancer [14] appeared to exhibit primary resistance to PPARγ targeted therapy.